Anonymous
01-30-2006, 09:16 AM
NEW YORK, Jan 30 (Reuters) - Schering-Plough Corp. (SGP.N: Quote, Profile, Research) on Monday said U.S. regulators agreed to review on a "fast-track" basis the company's marketing application for a new treatment for hepatitis C.
The company said the U.S. Food and Drug Administration would give an expedited review to the medicine, code-named SCH 503034. The drug is now in mid-stage trials among patients with the hard-to-treat genotype 1 strain of the virus who have not responded to standard treatments -- including Schering-Plough's widely used older combination therapy.
This is great news. This therapy will reveloutionize Hep C treatment and will probably still be used with Peg. This will come out and we'll kick ass with the protease and at the same time we'll get results from IDEAL.
More good news
The company said the U.S. Food and Drug Administration would give an expedited review to the medicine, code-named SCH 503034. The drug is now in mid-stage trials among patients with the hard-to-treat genotype 1 strain of the virus who have not responded to standard treatments -- including Schering-Plough's widely used older combination therapy.
This is great news. This therapy will reveloutionize Hep C treatment and will probably still be used with Peg. This will come out and we'll kick ass with the protease and at the same time we'll get results from IDEAL.
More good news